Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD264 Alexa Fluor® 647

Anti-Hu CD264 Alexa Fluor® 647

Anti-Hu CD264 Alexa Fluor® 647
Regulatory status
RUO
Antigen
CD264
Clone
TRAIL-R4-01
Format
Alexa Fluor® 647
Reactivity
Human
Application
FC (QC tested)
Excitation laser
red (633 nm)
Variant
0.1 mg
A6-519-C100
Ask for delivery term HERE
220.00 USD
Variant
0.1 mg
11-261-C100
In stock
220.00 USD
Contact distributor
Product details
Description
References
Isotype
Mouse IgG1
Specificity
The antibody TRAIL-R4-01 reacts with an extracellular epitope of TRAIL-R4, a 42 kDa transmembrane protein expressed on various blood cells.
Workshop
HLDA X
Application
FC (QC tested)
Application details
Flow cytometry: Recommended dilution: 1-5 μg/ml.
Reactivity
Human
Immunogen
TRAIL-R4 (aa 1-210) - hIgGhc fusion protein
Concentration
0.1 mg/ml
Preparation
The purified antibody is conjugated with Alexa Fluor® 647 under optimum conditions. The conjugate is purified by size-exclusion chromatography.
Formulation
Stabilizing phosphate buffered saline (PBS) solution containing 15 mM sodium azide
Storage and handling
Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Licence note
Alexa Fluor®, Pacific Blue™ and Pacific Orange™ are registered trademarks of Life Technologies Corporation.
Licence label
This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com.
Other names
TNFRSF10D, DcR2, TRUNDD, TRAILR4
Antigen description
TRAIL-R4 (CD264, TR4, DcR2, TRUNDD), expressed mainly on CD8+ and NK cells, belongs to receptors of TRAIL, a TNF-like membrane toxic protein that induces apoptosis in many tumour cells, but not in normal cells. TRAIL-R4, however, contains partially truncated death domain, thus it is unable to induce apoptosis and serves as a negative regulator of apoptotic signaling by impairment death-inducing signaling complex (DISC) processing. TRAIL-R4 interacts with death receptor 5 (DR5) in the native DISC in a TRAIL-dependent manner and prevents its corecruitment with death receptor 4 (DR4).
Entrez Gene ID 8793
UniProt ID Q9UBN6

General references:

Deligezer U, Dalay N: Expression of the TRAIL Receptors in Blood Mononuclear Cells in Leukemia. Pathol Oncol Res. 2007;13(4):290-4.
PubMed
Falschlehner C, Emmerich CH, Gerlach B, Walczak H: TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol. 2007;39(7-8):1462-75.
PubMed
Mérino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006 Oct;26(19):7046-55.
PubMed
Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer. 2005 May 25;5(1):54.
PubMed
Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G, Lenardo MJ, Chan FK: Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18099-104.
PubMed
Variant
0.1 mg
A6-519-C100
Ask for delivery term HERE
220.00 USD
Variant
0.1 mg
11-261-C100
In stock
220.00 USD
Contact distributor
Datasheet download
SDS download
Bulk requests
Technical support for this product